Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Bolt Biotherapeutics's Net Cash per Share or its related term are showing as below:
During the past 8 years, the highest Price-to-Net-Cash Ratio of Bolt Biotherapeutics was 4.88. The lowest was 0.44. And the median was 0.79.
BOLT's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 5.13 * Ranked among companies with meaningful Price-to-Net-Cash only.
Bolt Biotherapeutics (NAS:BOLT) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Bolt Biotherapeutics Net Cash per Share Related Terms
Bolt Biotherapeutics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Bolt Biotherapeutics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOLT vs NCNA, CELZ, CURX: Net Cash per Share Comparison
For the Biotechnology subindustry, Bolt Biotherapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bolt Biotherapeutics Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Bolt Biotherapeutics's Price-to-Net-Cash falls into.
Bolt Biotherapeutics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Bolt Biotherapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bolt Biotherapeutics (BOLT) has a Net Cash per Share of $-5.25 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Bolt Biotherapeutics and its competitors. According to the industry distribution chart, Bolt Biotherapeutics ranks #999999 out of 767 companies in the Biotechnology industry.
Is Bolt Biotherapeutics' Net Cash per Share too high?
Bolt Biotherapeutics' current Net Cash per Share is $-5.25. Based on the distribution chart, Bolt Biotherapeutics ranks #999999 out of 767 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bolt Biotherapeutics has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' Net Cash per Share compare to NCNA and CELZ?
According to the Biotechnology industry distribution chart, Bolt Biotherapeutics ranks #999999 out of 767 companies for Net Cash per Share. This places Bolt Biotherapeutics in the lower half of its industry. The industry median Net Cash per Share is 5.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.13, based on 767 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Bolt Biotherapeutics and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bolt Biotherapeutics's current Net Cash per Share is $-5.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bolt Biotherapeutics (BOLT) is currently considered Possible Value Trap. The stock's GF Value™ is $6.26, compared to a current price of $3.90 — trading 37.8% below its estimated fair value. The current Net Cash per Share is $-5.25. Bolt Biotherapeutics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Bolt Biotherapeutics (BOLT), the current Net Cash per Share is $-5.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bolt Biotherapeutics (BOLT) Overvalued in 2026?
Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued.
The current stock price of $3.90 is trading 37.8% below its estimated GF Value™ of $6.26.
GuruFocus considers Bolt Biotherapeutics to be Possible Value Trap.
Key valuation signals for BOLT:
Net Cash per Share: $-5.25
GF Value™: $6.26 vs. price of $3.90 (37.8% below fair value)
No single metric tells the full story. See the BOLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
59GF Score
Get the complete analysis for BOLT
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOLT has been successfully added to your 
